T cell regulation of immunoglobulin class expression in the antibody response to trinitrophenyl-ficoll. Evidence for T cell enhancement of the immunoglobulin class switch

P K Mongini, W E Paul, E S Metcalf, P K Mongini, W E Paul, E S Metcalf

Abstract

In the absence of T cells, B cells were found to respond to the type 2 T-independent (TI-2) antigen, trinitrophenyl (TNP)-Ficoll, with a characteristic hierarchy of IgM and IgG subclass Ab production which directly correlated with 5' to 3' Igh-C gene order, i.e., IgM greater tha IgG3 greater than IgG1 greater than IgG2b greater than IgG2a. This was evident when immune serum Ab titers were analyzed, when in vitro secretion of antibody from immune cells was measured and when TNP-Ficoll-stimulated clones in a splenic focus assay were analyzed for isotype production. T cells were found to cause a preferential relative increase in the amount of IgG2a antibody produced to TNP-Ficoll. The T cell responsible was present in anti-IgM neonatally suppressed mice and was needed early in the response, i.e., on the day of immunization or earlier. T cells were found to increase the frequency of TNP-Ficoll-responsive B cell clones that produced IgG2a in the splenic focus assay. The great majority of these IgG2a-positive clones also produced IgM and all or nearly all of the IgG isotypes whose genes are encoded 5' to the Igh-gamma 2a gene. The data are discussed in terms to T cell enhancement of IgG2a Ab synthesis being mediated through T cell enhancement of the Igh-C gene switching mechanism within TNP-Ficoll-responsive B cell clones. Thus, isotypes encoded by genes on the 3' end of the Igh-gamma gene complex, which in the absence of T cells have a low probability of being switched to, are the most influenced by T cell help.

References

    1. J Immunol. 1966 Sep;97(3):421-30
    1. Nature. 1968 Nov 30;220(5170):927-8
    1. J Immunol. 1971 May;106(5):1338-44
    1. J Exp Med. 1972 Jan;135(1):126-35
    1. J Immunol. 1973 Sep;111(3):720-32
    1. Proc Natl Acad Sci U S A. 1974 Feb;71(2):512-6
    1. Cell Immunol. 1976 Apr;23(1):140-57
    1. J Exp Med. 1976 Aug 1;144(2):330-44
    1. J Immunol Methods. 1977;15(1):47-56
    1. Immunology. 1977 Oct;33(4):485-90
    1. Proc Natl Acad Sci U S A. 1977 Oct;74(10):4582-6
    1. Science. 1978 Mar 10;199(4333):1078-80
    1. Adv Immunol. 1977;25:141-211
    1. J Exp Med. 1978 Jun 1;147(6):1744-54
    1. J Exp Med. 1979 Jan 1;149(1):216-27
    1. J Exp Med. 1979 Mar 1;149(3):632-43
    1. J Immunol. 1979 Apr;122(4):1203-8
    1. J Immunol. 1979 Jul;123(1):434-41
    1. J Immunol Methods. 1979;28(3-4):255-66
    1. Eur J Immunol. 1980 Feb;10(2):159-63
    1. J Exp Med. 1980 Apr 1;151(4):853-62
    1. J Exp Med. 1980 May 1;151(5):1071-87
    1. J Immunol. 1980 Sep;125(3):1066-70
    1. Science. 1980 Sep 19;209(4463):1360-5
    1. Eur J Immunol. 1980 Sep;10(9):698-702
    1. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5424-8
    1. J Exp Med. 1981 Jan 1;153(1):1-12
    1. Nature. 1981 Jan 15;289(5794):149-53
    1. Cell. 1981 Feb;23(2):357-68
    1. J Immunol. 1981 May;126(5):1952-7
    1. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1581-5

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren